Fidelity Investments
ACTU

Fidelity Investments’s Actuate Therapeutics ACTU Stock Holding History

Fidelity Investments’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.5K Buy
8,945
+8,665
+3,095% +$35.9K ﹤0.01% 4436
2025
Q4 		$1.71K Sell
280
-293
-51% -$2.01K ﹤0.01% 5034
2025
Q3 		$3.83K Buy
573
+262
+84% +$1.9K ﹤0.01% 4838
2025
Q2 		$1.9K Buy
+311
New +$2.72K ﹤0.01% 4866

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's ACTU Position: Q1 2026 in Review

Fidelity Investments increased its Actuate Therapeutics (ACTU) stake by 3,095% in Q1 2026, buying an estimated $35.9K and bringing the position to 8,945 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4436.

Fidelity Investments first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Fidelity Investments held 8,945 shares of Actuate Therapeutics worth $24.5K as of Q1 2026.
  • Fidelity Investments bought 8,665 Actuate Therapeutics shares in Q1 2026, an estimated $35.9K.
  • Actuate Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4436 holding.
  • Fidelity Investments first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.